Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Large Volume Increase – Should You Buy?

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) saw an uptick in trading volume on Wednesday. Approximately 1,247,992 shares traded hands during trading, an increase of 81% from the previous session’s volume of 688,695 shares. The stock last traded at $21.0190 and had previously closed at $22.42.

Analysts Set New Price Targets

Several research analysts recently issued reports on FMS shares. Sanford C. Bernstein increased their price objective on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Truist Financial set a $25.00 target price on Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, August 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 4th. BNP Paribas Exane downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price target on the stock. in a research report on Tuesday, July 28th. Finally, Berenberg Bank set a $24.00 price target on Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 29th. Seven investment analysts have rated the stock with a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $23.67.

Fresenius Medical Care AG & Co. KGaA Trading Down 7.3%

The company has a market capitalization of $11.17 billion, a PE ratio of 10.78, a price-to-earnings-growth ratio of 4.12 and a beta of 0.74. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75. The company’s fifty day moving average is $23.20 and its 200-day moving average is $22.93.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.04. The business had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. On average, analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.29 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several hedge funds have recently modified their holdings of FMS. Allworth Financial LP boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the 2nd quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock valued at $80,000 after buying an additional 850 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA during the second quarter valued at approximately $91,000. EverSource Wealth Advisors LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 50.3% in the first quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock valued at $93,000 after acquiring an additional 1,383 shares in the last quarter. Parallel Advisors LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 27.9% in the first quarter. Parallel Advisors LLC now owns 4,632 shares of the company’s stock valued at $104,000 after acquiring an additional 1,011 shares in the last quarter. Finally, Kathmere Capital Management LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the first quarter valued at approximately $219,000. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.